ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN wishes from three weeks ago..

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Apr 16, 2021 6:38am

150 Views

Post# 33009303

RE:RE:RE:RE:PMN wishes from three weeks ago..

The long and short of it....... Clinical Trial....... Clinical Trial......Clinical Trial.

The new investors need to put up more cash and get things going if their goal is to list PMN on Nasdaq.

G1945V

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments